Actelion seeking Tracleer approval in Japan

Actelion (SWX:ATLN) filed for Japanese approval of its Tracleer bosentan oral endothelin receptor antagonist to treat pulmonary arterial hypertension (PAH). ATLN expects to launch the product by year ...